273 related articles for article (PubMed ID: 34263385)
1. Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension.
Muz OE; Dagdelen K; Pirdal T; Guler M
Int Ophthalmol; 2021 Nov; 41(11):3825-3835. PubMed ID: 34263385
[TBL] [Abstract][Full Text] [Related]
2. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
Aihara M; Ikeda Y; Mizoue S; Arakaki Y; Kita N; Kobayashi S;
J Glaucoma; 2016 Jun; 25(6):e610-4. PubMed ID: 25967526
[TBL] [Abstract][Full Text] [Related]
3. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
4. From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability.
Rossi GC; Scudeller L; Rolle T; Pasinetti GM; Bianchi PE
Expert Opin Drug Saf; 2015 May; 14(5):619-23. PubMed ID: 25759110
[TBL] [Abstract][Full Text] [Related]
5. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
Aihara M; Oshima H; Araie M;
Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
[TBL] [Abstract][Full Text] [Related]
6. Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost.
Kumar S; Singh T; Ichhpujani P; Vohra S
Rom J Ophthalmol; 2019; 63(3):249-256. PubMed ID: 31687627
[No Abstract] [Full Text] [Related]
7. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
[TBL] [Abstract][Full Text] [Related]
8. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.
Nagstrup AH
Acta Ophthalmol; 2023 Dec; 101 Suppl 278():3-21. PubMed ID: 38037546
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
10. Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical/pharmacy claims databases.
Schwartz GF; Kotak S; Mardekian J; Fain JM
BMC Ophthalmol; 2011 Jun; 11():14. PubMed ID: 21672240
[TBL] [Abstract][Full Text] [Related]
11. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
Crichton AC; Vold S; Williams JM; Hollander DA
Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
[TBL] [Abstract][Full Text] [Related]
12. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
Wong TT; Aung T; Ho CL
Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
[TBL] [Abstract][Full Text] [Related]
13. The Effects of Latanoprost With Benzalkonium Chloride Versus Travoprost With SofZia on the Ocular Surface.
Rahmatnejad K; Rapuano CJ; Ichhpujani P; Wizov SS; Moster MR; Hark LA; Katz LJ
Eye Contact Lens; 2018 Nov; 44 Suppl 2():S93-S98. PubMed ID: 28617732
[TBL] [Abstract][Full Text] [Related]
14. Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions.
Liang H; Brignole-Baudouin F; Riancho L; Baudouin C
Ophthalmic Res; 2012; 48(2):89-101. PubMed ID: 22473057
[TBL] [Abstract][Full Text] [Related]
15. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
16. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues.
El Ameen A; Vandermeer G; Khanna RK; Pisella PJ
Eur J Ophthalmol; 2019 Nov; 29(6):645-653. PubMed ID: 30301370
[TBL] [Abstract][Full Text] [Related]
17. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost.
Katz G; Springs CL; Craven ER; Montecchi-Palmer M
Clin Ophthalmol; 2010 Nov; 4():1253-61. PubMed ID: 21151330
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial.
Koz OG; Ozsoy A; Yarangumeli A; Kose SK; Kural G
Acta Ophthalmol Scand; 2007 Dec; 85(8):838-43. PubMed ID: 17680841
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells.
Brignole-Baudouin F; Riancho L; Liang H; Baudouin C
Curr Eye Res; 2011 Nov; 36(11):979-88. PubMed ID: 21999224
[TBL] [Abstract][Full Text] [Related]
20. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
Konstas AG; Boboridis KG; Kapis P; Marinopoulos K; Voudouragkaki IC; Panayiotou D; Mikropoulos DG; Pagkalidou E; Haidich AB; Katsanos A; Quaranta L
Adv Ther; 2017 Jan; 34(1):221-235. PubMed ID: 27913991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
